The adhesion GPCR Adgrd1 is a prion protein receptor and a mediator of prion cytotoxicity

In prion diseases, the cellular prion protein PrP$^{C}$is converted into aggregates of PrP$^{Sc}$, leading to profound neurotoxicity through largely unknown mechanisms. Here we report that the cellular prion protein PrP$^{C}$acts as an antagonist of the adhesion G protein-coupled receptor (GPCR) Adgrd1. When overexpressed in cultured cells, Adgrd1 recruited the G-protein Gαs, inducing excessive cytosolic cAMP, growth arrest and cytotoxicity, all of which were suppressed by FT$_{25-50}$, a 26-meric peptide from the N-terminal flexible tail (FT) of PrP$^{C}$. We found that FT$_{25-50}$forms a complex with Adgrd1 and suppresses its intrinsic activation by the Stachel peptide. Adgrd1 ablation attenuated the neurodegeneration of prion-infected cerebellar organotypic slice cultures and prolonged the healthspan of prion-infected mice. Interaction studies with mutated proteins, computational modeling and docking studies revealed that suppression of Adgrd1 signaling requires the polybasic domain of the FT and the N-terminal fragment of Adgrd1. In the absence of PrP$^{C}$, the cAMP spike caused by Adgrd1 was suppressed by co-expression of a functionally dead Adgrd1-Adgrg6 chimeric receptor, suggesting that Adgrd1 activation requires an unidentified agonistic ligand displaced by FT$_{25-50}$. These results identify Adgrd1 as a mediator of prion toxicity and suggest that Adgrd1 modulators may be beneficial against prion-related neurodegeneration

An arrayed genome-wide perturbation screen identifies the ribonucleoprotein Hnrnpk as rate-limiting for prion propagation.

Funder: Donation from the Estate of Dr Hans SalvisbergFunder: Nomis Foundation; Id: http://dx.doi.org/10.13039/501100008483A defining characteristic of mammalian prions is their capacity for self-sustained propagation. Theoretical considerations and experimental evidence suggest that prion propagation is modulated by cell-autonomous and non-autonomous modifiers. Using a novel quantitative phospholipase protection assay (QUIPPER) for high-throughput prion measurements, we performed an arrayed genome-wide RNA interference (RNAi) screen aimed at detecting cellular host-factors that can modify prion propagation. We exposed prion-infected cells in high-density microplates to 35,364 ternary pools of 52,746 siRNAs targeting 17,582 genes representing the majority of the mouse protein-coding transcriptome. We identified 1,191 modulators of prion propagation. While 1,151 modified the expression of both the pathological prion protein, PrPSc , and its cellular counterpart, PrPC , 40 genes selectively affected PrPSc . Of the latter 40 genes, 20 augmented prion production when suppressed. A prominent limiter of prion propagation was the heterogeneous nuclear ribonucleoprotein Hnrnpk. Psammaplysene A (PSA), which binds Hnrnpk, reduced prion levels in cultured cells and protected them from cytotoxicity. PSA also reduced prion levels in infected cerebellar organotypic slices and alleviated locomotor deficits in prion-infected Drosophila melanogaster expressing ovine PrPC . Hence, genome-wide QUIPPER-based perturbations can discover actionable cellular pathways involved in prion propagation. Further, the unexpected identification of a prion-controlling ribonucleoprotein suggests a role for RNA in the generation of infectious prions

Palmitoylated calnexin is a key component of the ribosome-translocon complex.

A third of the human genome encodes N-glycosylated proteins. These are co-translationally translocated into the lumen/membrane of the endoplasmic reticulum (ER) where they fold and assemble before they are transported to their final destination. Here, we show that calnexin, a major ER chaperone involved in glycoprotein folding is palmitoylated and that this modification is mediated by the ER palmitoyltransferase DHHC6. This modification leads to the preferential localization of calnexin to the perinuclear rough ER, at the expense of ER tubules. Moreover, palmitoylation mediates the association of calnexin with the ribosome-translocon complex (RTC) leading to the formation of a supercomplex that recruits the actin cytoskeleton, leading to further stabilization of the assembly. When formation of the calnexin-RTC supercomplex was affected by DHHC6 silencing, mutation of calnexin palmitoylation sites or actin depolymerization, folding of glycoproteins was impaired. Our findings thus show that calnexin is a stable component of the RTC in a manner that is exquisitely dependent on its palmitoylation status. This association is essential for the chaperone to capture its client proteins as they emerge from the translocon, acquire their N-linked glycans and initiate folding